We would love to hear your thoughts about our site and services, please take our survey here.
As the SP hinges massively on FDA approval the constant delay is a worry. Clearly Angle board assumes its now just a buereaucratic delay caused by initial lack of reagents and covid absences at the FDA labs and office.. Concern might however be expressed regrding this appearing to be almost the last ,if not the last of 60 de novo applications to be granted, if at all. One wonders whether there is an element of "Not invented here" allowing some sort of comptetive catch up or if there are any genuine concerns causing the excessive delay now? As I have also bought more, the longer we wait the more twitchy I get. Oh to be a fly on the wall in the FDA office.
Angle has an extremely strong technical and medical case. Multiple centres of excellence and leaders in Oncology have attested to the ease of collecting CTC's and analysis together with improved efficacy. The concerns are that the FDA will withhold approval for a new device longer than they might for a US invented item. Secondly whether the lab service can deliver significant returns and logistically handle the possible volume of samples in a timely manner. Clearly the FDA is the key to the SP. and one wonders is it might just be coincident with Sept 23oth results announcement. Why it should have gone from a high of 140P is anyone's guess and the approval is apparently only for research into Breast cancer usage , albeit a mighty area on its own, but ovarian and other lung cancers are fields of immense potential for life saving better strategies for treatment based upon blood analysis, using the Parsortix device. One hopes approval is not overly long delayed and is given for further use in the field. Where that leaves the SP is dependent upon subsequent take up of products and services and the possibility of a potential bid from more than one suitor, less any copies built avoiding patent dispute.
The inference would be wait and see, but further positive news/ approval misses an interesting ride.
Preparing to meet demand unfortunately demonstrates that it s not ready to do so yet. Hopefully they will be able to do so over a short period, but " in due course" does not sound as if that's a starter. Stockouts, logistical problems, maintaining quality lines of supply are all critical even mores so with new product lines until they are established with customer preferences and loyalty, We are all aware of inferior products winning the marketing and merchandising battle and with todays amalgamation Tifaly will be serious opposition.
Our management needs to really be on the ball in ensuring hey do not initially overtrade, a buffer stock is available at very short notice, the logistics are in place, for the size of market they intend to address,
I have today bought more shares on the basis that this will take place and we are kept informed. There may be a temporary fall in SP if no Brexit deal takes place by the weekend even though its highly irrelevant, just a general readjustment. Without any short term confirmation of agreed supply and sales data I may reduce my holding., and take some profit now.
If rolled out to 88000 outlets selling up to 10 plus items a day average, is the supply of the demanded high quality hemp sufficient to meet nearly 6 M items a week? How big a growing area is required? I'm a genuine holder of these shares, and have been adding gradually, but would seriously like to understand any potential pitfalls on supply and logistics..Anyone?
I hope its extremely temporarily. When relying on external suppliers of the raw material you can become a hostage to fate, If they are overtrading on the back of thousands of new stockists, rather than a manged roll out ,the easiest and quickest way to **** off retail outlet partners and customers alike is to repeatedly fail to meet demand by repeated stock outs. I am a buyer too!